Internal Medicine · San Bernardino, CA
NPI
1184636235
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
399 E Highland Ave Ste 227
San Bernardino, CA, 92404
Phone (909) 882-1210
Groups this clinician bills Medicare through
Medicare paid, 2024
$95K
1,164 services
Medicare patients, 2024
385
Average age 71
Drug cost, 2024
$5.1M
11,080 prescriptions
Company payments, 2025
$12K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tony Kastoon was code 99214 (office e&m - established), 851 times for 361 patients. In total Tony Kastoon billed 1,164 services in 15 codes, and Medicare paid $95K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-01-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 851 | 361 | $94.24 | $80K |
| 95251 Test - Miscellaneous | Office | 154 | 66 | $27.21 | $4,191 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 51 | 51 | $13.19 | $673 |
| 76536 Ultrasound - Nonspecific | Office | 39 | 38 | $82.13 | $3,203 |
| 99205 Office E&M - New | Office | 17 | 17 | $152.46 | $2,592 |
| 99204 Office E&M - New | Office | 15 | 15 | $120.36 | $1,805 |
By year: 2022 $130K for 1,417 services; 2023 $113K for 1,269 services; 2024 $95K for 1,164 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 19 | 14 | $3.07 | $58.26 |
Medicare prescription drug claims, 2024
In 2024, the drug Tony Kastoon prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,042 prescriptions and refills. In total Tony Kastoon wrote 11,080 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,042 | 2,392 | 283 | $12K |
| Ozempic Semaglutide | 847 | 1,123 | 199 | $1.0M |
| Metformin Hcl Generic | 549 | 1,263 | 178 | $4,554 |
| Mounjaro Tirzepatide | 376 | 426 | 67 | $439K |
| Jardiance Empagliflozin | 330 | 563 | 100 | $319K |
| Trulicity Dulaglutide | 319 | 393 | 73 | $369K |
| Metformin Hcl Er Metformin Hcl | 305 | 640 | 89 | $3,063 |
| Synthroid Levothyroxine Sodium | 284 | 634 | 80 | $21K |
| Pioglitazone Hcl Generic | 276 | 550 | 85 | $1,928 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 272 | 457 | 73 | $31K |
| Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro | 263 | 409 | 67 | $57K |
| Humalog Kwikpen U-100 Insulin Lispro | 222 | 417 | 76 | $56K |
| Farxiga Dapagliflozin Propanediol | 203 | 293 | 48 | $159K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 198 | 426 | 79 | $19K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 169 | 278 | 37 | $149K |
Brand drugs: 6,168 claims; generic drugs: 4,159 claims; opioid claims: 35.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tony Kastoon $12K ($12K in general payments such as food, travel and fees) from 33 companies. The largest payer was Amgen Inc. with $6,491.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 36 | $6,491 |
| Abbott Laboratories ABT | 30 | $750 |
| Dexcom, Inc. DXCM | 67 | $747 |
| Novo Nordisk Inc NVO | 27 | $520 |
| Ascendis Pharma Endocrinology Inc ASND | 25 | $379 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 20 | $331 |
| Madrigal Pharmaceuticals MDGL | 9 | $291 |
| Mannkind Corporation MNKD | 13 | $223 |
| Recordati_rare_diseases_inc. | 16 | $173 |
| Abbvie Inc. ABBV | 10 | $159 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.